MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today

Clinical Trials
Locations
Careers
Contact Us
Our Doctors
- Español
- عربى
- 中文
- Türkçe

Clear

close

Search MD Anderson

MyChart

Donate Today

Clinical Trials
Locations
Careers
Contact Us
- Español
- عربى
- 中文
- Türkçe

Request an Appointment
New Patients
Current Patients
Referring Physicians

Patients & Family
Prevention & Screening
Donors & Volunteers
For Physicians
Research
Education & Training

Departments, Labs and Institutes
Labs
Allison Laboratory
Lab Members

Top

Jump To:

Back

Allison Laboratory
- Publications
- Lab Members
- Life in the Lab

Allison Lab Members

Jim Allison - email
Regental Professor and Chair

Shirley Lindsey - email
Program Manager and Assistant to Dr. Allison

Naveen Sharma - email
Sr. Research Scientist

Didem Çobanoğlu - email
Odyssey Fellow
Dr. Agac's Publications

My research focuses on finding novel immunosuppressive pathways in the tumor microenvironment. My previous research has shown that the signaling through adrenergic receptors impair adaptive and innate immune cells’ function and promote immunosuppression. I am currently investigating the role of neurotransmitters in the tumor microenvironment and trying to uncover novel immunosuppressive pathways that can be targeted by repurposing drugs.

Dr.. Çobanoğlu is PI on an MRF Breakthrough Consortium-Bristol Myers Squibb Young Investigator Research Team Award to Advance the Field of Translational Immuno-Oncology.

Stephen Mok - email
Instructor
Dr. Mok's publications

My goal is to understand the long-term effect of immune checkpoint blockade therapy. Anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) treatment induces a low response rate (~11%), while anti-programmed cell death-1 (anti-PD-1) treatment mediates a relatively higher response rate (~30%) in patients with melanoma. Both anti-CTLA-4 and anti-PD-1 induce durable responses and mediate a 22% 10-year and 34% 5-year survival rate respectively. However, in order to achieve the durable response, continuous treatment of anti-PD-1 has to be administered while anti-CTLA-4 treatment can only be administered for a short period of time. In addition, 25% of patients who initially respond to these treatment relapse within 2 years. Therefore, it is important to understand the differential effect of checkpoint blockade treatments on the formation of immunological memory.